The Mail reported that Lindell wooed Krakowski, but the lawsuit says that the story has caused him emotional distress as a recovering addict.
8
An independent review found that neither Black nor Apollo employees had been involved with Epstein's criminal activities.
10
Ken Endo is the CEO of Xiborg, a company that specializes in creating prosthetic limbs for athletes.
5
QVC confirmed it stopped selling MyPillow products in June 2020, citing the company's strategy of providing an ever changing portfolio of products.
8
QVC confirmed it stopped selling MyPillow products in June 2020, citing the company's strategy of providing an ever changing portfolio of products.
3
John Krafcik called Tesla's approach a "misconception," while Google's sister company tackles lidar and more advanced systems.
3
Earlier this year, Waymo dropped "self-driving" from its vocabulary, saying "some automakers use the term in an inaccurate way."
1
Earlier this year, Waymo dropped "self-driving" from its vocabulary, saying "some automakers use the term in an inaccurate way."
7
When it comes to memes and the art of emoji, you're probably doing it wrong, says Tiffany Zhong, who sat down with a16z's Connie Chan.
5
When it comes to memes and the art of emoji, you're probably doing it wrong, says Tiffany Zhong, who sat down with a16z's Connie Chan.
9
With public trust in government leaders falling short, alongside wariness of disinformation, employers are expected to step up to bring stabilization. The post The role of the CEO is expanding as people turn to business leaders for stability in time of social uncertainty appeared first on Digiday.
8
Waymo CEO John Krafcik said Tesla is "no competitor at all" for its autonomous vehicles, according an interview with Germany's Manager Magazin.
6
Gorman's total pay increased to $33 million in 2020, passing the $31.5 million earned by JPMorgan CEO Jamie Dimon.
5
Elon Musk and John Krafcik have very different theories about driverless tech.
4
MyPillow CEO Mike Lindell is threatening to take legal action against the Daily Mail following a report he dated actress Jane Krakowski.
5
Many other retailers have dropped the brand following CEO Mike Lindell's false claims of election fraud in support of former President Donald Trump.
10
Away CEO Stuart Haselden will step down in February, according to a company press release. The luggage brand’s president and co-founder, Jen Rubio, will take over as interim chief executive until Away finds a permanent replacement. The news was first reported by Axios. Haselden, a former Lululemon executive, joined the company in the wake of a Verge investigation, which found that former employees were critical of then-CEO Steph Korey’s management style. Korey stepped down shortly after this investigation, then retook her post and threatened to sue The Verge for defamation. Haselden and Korey served as co-CEOs until Korey resigned again in October. Haselden told employees that he is leaving to pursue another opportunity, Axios reports.... Continue reading…
9
Advances in the medical device industry have led to a substantial increase in developmental complexity, clinical trial conduct, and stringency of regulatory review, causing sponsors to rely on the technical and regulatory affairs management expertise of CROs Roots Analysis is pleased to announce the publication of its recent study, titled, “Medical Device CRO Market (2nd Edition), 2020-2030”.The report features an extensive study of the current market landscape and future opportunities of contract research service providers focused on medical devices.The study also features an in-depth analysis, highlighting the capabilities of the various stakeholders engaged in this domain, across different regions of the globe.In addition to other elements, the study includes:A detailed review of the overall landscape of medical device CROs.An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America, Europe, and Asia-Pacific and rest of the world.Elaborate profiles of key players that specialize in offering services for both clinical and preclinical stage development of medical devices.An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers engaged in this domainA competitive benchmarking, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups.A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of service portfolio).A detailed geographical clinical trial analysis of ongoing and planned studies related to medical devices.A detailed analysis of the mergers and acquisitions that have taken place in this domain during the period 2015-2020.A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract research services to medical device developers.A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.An elaborate discussion on the future opportunities / trends for the medical device outsourcing market that are likely to influence the growth of this domain over the coming years.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Phase of Development ClinicalPreclinical Types of Preclinical Services OfferedBiocompatibility testingSterility and microbiology testingMaterial characterization and analytical servicesOthers Types of Clinical Services OfferedClinical trial managementData managementRegulatory affairs managementConsultingOthers Device ClassClass I medical devicesClass II medical devicesClass III medical devices Target Therapeutic AreaCNS disordersCardiovascular disordersOncological disordersBone disordersRespiratory disordersPain management disordersOphthalmic disordersPsychological disordersMetabolic disordersOthers Key Geographical RegionsNorth AmericaEuropeAsia-PacificRest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companiesLajos Sarosi (Chief Executive Officer and Co-founder, HungaroTrial)Christopher Rupp (Vice President of Global Marketing and Commercial Operations, NAMSA)Christian Wolflehner (General Manager, CW Research & Management)Troy Mccall (Chief Operating Officer, CROMSOURCE)Nazish Urooj (Senior manager, Medical & Clinical Operations, Metrics Research)Omprakash (Technical Director and Partner, Vyomus Consulting)Tania Persson (Director of Business Development, A+ Science)Alexa Foltin-Mertgen (Business Development Manager, AtoZ-CRO) Key companies covered in the reportAvania (formerly known as Factory CRO)Charles River LaboratoriesClinlogixCROMSOURCECSSi LifeSciences™Eurofins Medical Device TestinggenaeIMARC ResearchIQVIAMedpaceNAMSAQserve GroupRegulatory and Clinical Research Institute (now a part of Covance)WuXi AppTec For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html Other Recent OfferingsContract Regulatory Affairs Management Market for Medical Devices, 2019-2030Medical Device Labels Manufacturing Market, 2019 - 2030Medical Device Contract Manufacturing Market, 2019-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
To order this detailed 670+ page report, please visit this link Key InclusionsA detailed review of the overall landscape of gene therapies and genome editing therapies, including information on various drug / therapy developer companies, phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, key therapeutic areas (cardiovascular disorders, muscular disorders, neurological disorders, ocular disorders, oncology and others) and target disease indication(s), information on gene type, type of vector used, type of therapy (ex vivo and in vivo), mechanism of action, type of gene modification (gene augmentation, oncolytic viral therapy and others) and special drug designation (if any).A discussion on the various types of viral and non-viral vectors, along with information on design, manufacturing requirements, advantages, limitations and applications of currently available gene delivery vectors.A world map representation, depicting the most active geographies, in terms of the presence of companies engaged in developing gene therapies, and a bull's eye analysis, highlighting the distribution of clinical-stage pipeline candidates by phase of development, type of vector and type of therapy (ex vivo and in vivo).A discussion on the regulatory landscape related to gene therapies across various geographies, namely North America (the US and Canada), Europe and Asia-Pacific (Australia, China, Japan and South Korea), providing details related to the various challenges associated with obtaining reimbursements for gene therapies.Detailed profiles of marketed and phase II/III and gene therapies, including a brief history of development, information on current development status, mechanism of action, affiliated technology, strength of patent portfolio, dosage and manufacturing details, along with information on the developer company.An elaborate discussion on the various commercialization strategies that can be adopted by drug developers for use across different stages of therapy development, namely prior to drug launch, at / during drug launch and post-marketing.A review of various emerging technologies and therapy development platforms that are being used to design and manufacture gene therapies, featuring detailed profiles of technologies that were / are being used for the development of four or more products / product candidates.An in-depth analysis of the various patents that have been filed / granted related to gene therapies and genome editing therapies, since 2016.The analysis also highlights the key parameters associated with the patents, including information on patent type (granted patents, patent applications and others), publication year, regional applicability, CPC classification, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.An analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019.The analysis also provides information on the key value drivers and deal multiples related to the mergers and acquisitions that we came across.An analysis of the investments made at various stages of development in companies that are focused in this area, between 2014-2019, including seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings.An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of gene therapies under development, funding information, partnership activity and strength of patent portfolio.A case study on the prevalent and emerging trends related to vector manufacturing, with information on companies offering contract services for manufacturing vectors.The study also includes a detailed discussion on the manufacturing processes associated with various types of vectors.A discussion on the various operating models adopted by gene therapy developers for supply chain management, highlighting the stakeholders involved, factors affecting the supply of therapeutic products and challenges encountered by developers across the different stages of the gene therapy supply chain.An analysis of the various factors that are likely to influence the pricing of gene-based therapies, featuring different models / approaches that may be adopted by manufacturers to decide the prices of these therapies.The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:Key therapeutic areasAutoimmune disordersCardiovascular diseasesGenetic disordersHematological disordersMetabolic disordersOphthalmic disordersOncological disordersOthers Type of vectorAdeno associated virusAdenovirusHerpes simplex virus type 1LentivirusPlasmid DNARetrovirusVaccinia Virus Type of therapyEx vivoIn vivo Type of gene modificationGene augmentationImmunotherapyOncolytic therapyOthers Route of administrationIntraarticularIntracerebellarIntramuscularIntradermalIntravenousIntravitrealIntravesicalSubretinalOthers Key geographical regionsNorth AmericaEuropeAsia-Pacific The report includes detailed transcripts of discussions held with the following experts:Adam Rogers (CEO, Hemera Biosciences)Al Hawkins (CEO, Milo Biotechnology)Buel Dan Rodgers (Founder & CEO, AAVogen)Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)Christopher Reinhard (CEO and Chairman, Cardium Therapeutics)Ryo Kubota (Chairman, President and Chief Executive Officer, Acucela)Jeffrey Hung (CCO, Vigene Biosciences)Marco Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)Michael Triplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics)Robert Jan Lamers (CEO, Arthrogen)Tom Wilton (Chief Business Officer, LogicBio Therapeutics) To request sample pages, please visit this link               Key Questions AnsweredWho are the leading industry players in this market?How big is the development pipeline and which new indications are coming in focus?Which vectors are being used for effective delivery of the therapeutic agents?Who are the key investors in the gene therapy market?How is the current and future market opportunity likely to be distributed across key market segments?What kind of commercialization strategies are being adopted by gene therapy developers?What are the different pricing models and reimbursement strategies used for gene therapies?What are the prevalent R trends related to gene therapies?What are the various technology platforms that are either available in the market or are being designed for the development of gene therapies?Who are the key CMOs / CDMOs that claim to supply viral / plasmid vectors for gene therapy development?
With multiple approved products, the field of gene therapies has gained substantial momentum over the last couple of decades; innovator companies are gradually progressing their proprietary therapy candidates with cautious optimism Roots Analysis is pleased to announce the publication of its recent study, titled, “Gene Therapy Market (3rd Edition), 2019-2030”.The report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies and genome editing therapies.In addition to other elements, the study includes:A detailed review of the overall landscape of gene therapies and genome editing therapies.A discussion on the various types of viral and non-viral vectors.A world map representation, depicting the most active geographies, and a bull’s eye analysis, highlighting the distribution of clinical-stage pipeline candidates by phase of development, type of vector and type of therapy.A discussion on the regulatory landscape related to gene therapies across various geographies.Detailed profiles of marketed and phase II/III and gene therapies.An elaborate discussion on the various commercialization strategies that can be adopted by drug developers for use across different stages of therapy development.A review of various emerging technologies and therapy development platforms that are being used to design and manufacture gene therapies.An in-depth analysis of the various patents that have been filed / granted related to gene therapies and genome editing therapies, since 2016.An analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019.An analysis of the investments made at various stages of development in companies that are focused in this area, between 2014-2019.An analysis of the big biopharma players engaged in this domain.A case study on the prevalent and emerging trends related to vector manufacturing, with information on companies offering contract services for manufacturing vectors.A discussion on the various operating models adopted by gene therapy developers for supply chain management.An analysis of the various factors that are likely to influence the pricing of gene-based therapies.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Key therapeutic areasAutoimmune disordersCardiovascular diseasesGenetic disordersHematological disordersMetabolic disordersOphthalmic disordersOncological disordersOthersType of vectorAdeno associated virusAdenovirusHerpes simplex virus type 1LentivirusPlasmid DNARetrovirusVaccinia VirusType of therapyEx vivoIn vivoType of gene modificationGene augmentationImmunotherapyOncolytic therapyOthersRoute of administrationIntraarticularIntracerebellarIntramuscularIntradermalIntravenousIntravitrealIntravesicalSubretinalOthersKey geographical regionsNorth AmericaEuropeAsia-PacificTranscripts of interviews held with the following senior level representatives of stakeholder companiesAdam Rogers (CEO, Hemera Biosciences)Al Hawkins (CEO, Milo Biotechnology)Buel Dan Rodgers (Founder & CEO, AAVogen)Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)Christopher Reinhard (CEO and Chairman, Cardium Therapeutics)Ryo Kubota (Chairman, President and Chief Executive Officer, Acucela)Jeffrey Hung (CCO, Vigene Biosciences)Marco Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)Michael Triplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics)Robert Jan Lamers (CEO, Arthrogen)Tom Wilton (Chief Business Officer, LogicBio Therapeutics) Key companies covered in the reportAdvantageneAdvaxisBioMarinbluebird bioFKD TherapiesFreeline TherapeuticsGenSight BiologicsGradalisInovio PharmaceuticalsMarsala BiotechOrchard TherapeuticsPfizerSarepta TherapeuticsSpark TherapeuticsTocagenTransgeneuniQure BiopharmaVBL TherapeuticsViroMed For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html Other Recent OfferingsViral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)CAR-T Therapies Market (2nd Edition), 2019-2030Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected] 
More

Top